Table 1

Basic characteristics of trials included in the present study
Author Publication years Country Chemotherapy regimens Chemotherapy group (number of death/total) Surgery group (number of death/total) Follow-uptime (months) Chemotherapy group (number of R0/total) Surgery group (number of R0/total) Peritoneal recurrence in chemotherapy group Peritoneal recurrence in surgery group
1 Koga S[16] 1988 Japan 8-10 μg/ml MMC, 8-12 L, 50-60 min, 44-45°C 4/26 7/21 30 26/26 21/21 NA NA
2 Hamazoe R[17] 1993 Japan 10 μg/ml MMC, 10-12 L, 50-60 min, 48-50°C 18/42 22/40 77 40/42 35/40 7* 13*
3 Fujimura T[18] 1994 Japan 30 mg MMC + 300 mg CDDP, 6-8 L,60 min, 41-42°C 7/22 14/18 36 NA NA 2* 4*
4 Ikeguchi M[19] 1995 Japan 8-10 μg/ml MMC, 8-10 L, 50-60 min, 44-45°C 38/78 52/96 60 78/78 96/96 27* 38*
5 Fujimoto S[20] 1998 Japan 10 μg/ml MMC, 3-4 L, 120 min, 44.5-45°C 27/71 36/70 96 67/71 65/70 1* 16*
6 Yonemura Y[21] 2001 Japan 30 mgMMC + 300 mg CDDP, 6-8 L, 60 min, 42-43°C 19/48 27/47 60 48/48 47/47 6 7
7 Zuo Y[22] 2004 China 80-100 mg CDDP + 1000 mg 5-FU + 5 mg, 2 L,60 min, 41–43°C 8/46 14/36 36 NA NA NA NA
8 Wei G[23] 2005 China 1000 μg/ml 5-UF, 4-5 L, 60 min, 43-45°C 21/42 25/46 36 40/49 49/55 NA NA
9 Zhang GY[24] 2007 China 30 mg MMC + 300 mg CDDP, 2 L, 30 min, 42-45°C 44/92 75/120 60 92/92 120/120 13 45
10 Deng HJ[25] 2009 China 300-500 μg/ml 5-FU, 3 L, 60-90 min, 42-43°C 18/44 27/41 60 44/44 41/41 NA NA

*: The number of patients dead from peritoneal recurrence.

Sun et al.

Sun et al. BMC Cancer 2012 12:526   doi:10.1186/1471-2407-12-526

Open Data